Repurposing Verapamil to Enhance Killing of T-ALL Cells by the mTOR Inhibitor Everolimus

New therapies are needed for patients with T-cell lymphoblastic leukemia (T-ALL) who do not respond to standard chemotherapy. Our previous studies showed that the mTORC1 inhibitor everolimus increases reactive oxygen species (ROS) levels, decreases the levels of NADPH and glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme of the pentose phosphate pathway (PPP), and induces apoptosis in T-ALL cells. Studies in T-ALL-xenografted NOD/SCID mice demonstrated that everolimus improved their response to the glucocorticoid (GC) dexamethasone. Here we show that verapamil, a calcium antagonist used in the treatment of supraventricular tachyarrhythmias, enhanced the effects of everolimus on ROS and cell death in T-ALL cell lines. The death-enhancing effect was synergistic and was confirmed in assays on a panel of therapy-resistant patient-derived xenografts (PDX) and primary samples from T-ALL patients. The verapamil-everolimus combination produced a dramatic reduction in the levels of G6PD and induction of p38 MAPK phosphorylation. Studies of NOD/SCID mice inoculated with refractory T-ALL PDX cells demonstrated that the addition of verapamil to everolimus plus dexamethasone significantly reduced tumor growth in vivo. Taken together, our results provide a rationale for repurposing verapamil in association with mTORC inhibitors and GC to treat refractory T-ALL.

[1]  A. Trumpp,et al.  Therapy resistance mechanisms in hematological malignancies , 2022, International journal of cancer.

[2]  J. Hell,et al.  Cavβ1 regulates T cell expansion and apoptosis independently of voltage-gated Ca2+ channel function , 2022, Nature Communications.

[3]  A. Corradin,et al.  mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells , 2022, Redox biology.

[4]  J. Cook,et al.  Stress Relief Techniques: p38 MAPK Determines the Balance of Cell Cycle and Apoptosis Pathways , 2021, Biomolecules.

[5]  R. Callaghan,et al.  Exploiting the metabolic energy demands of drug efflux pumps provides a strategy to overcome multidrug resistance in cancer. , 2021, Biochimica et biophysica acta. General subjects.

[6]  M. Zoratti,et al.  Targeting mitochondrial ion channels for cancer therapy , 2020, Redox biology.

[7]  V. Costa,et al.  The Multifaceted Role of Annexin A1 in Viral Infections , 2023, Cells.

[8]  G. Basso,et al.  Selective killing of human T-ALL cells: an integrated approach targeting redox homeostasis and the OMA1/OPA1 axis , 2018, Cell Death & Disease.

[9]  J. McCubrey,et al.  Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update , 2018, International Journal of Molecular Sciences.

[10]  B. Johansson,et al.  Pediatric T‐cell acute lymphoblastic leukemia , 2017, Genes, chromosomes & cancer.

[11]  Dennis Wang,et al.  Combenefit: an interactive platform for the analysis and visualization of drug combinations , 2016, Bioinform..

[12]  I. Pastan,et al.  The Role of Multidrug Resistance Efflux Pumps in Cancer: Revisiting a JNCI Publication Exploring Expression of the MDR1 (P-glycoprotein) Gene. , 2015, Journal of the National Cancer Institute.

[13]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[14]  A. Gurney,et al.  Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts , 2014, Leukemia.

[15]  R. Lock,et al.  Glucocorticoid resistance in paediatric acute lymphoblastic leukaemia , 2012, Journal of paediatrics and child health.

[16]  K. Chandy,et al.  Inhibitors of mitochondrial Kv1.3 channels induce Bax/Bak-independent death of cancer cells , 2012, EMBO molecular medicine.

[17]  Michael M Gottesman,et al.  Collateral sensitivity as a strategy against cancer multidrug resistance. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[18]  F. Antunes,et al.  Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells , 2011, Leukemia.

[19]  L. Chieco‐Bianchi,et al.  Redox regulation of T-cell turnover by the p13 protein of human T-cell leukemia virus type 1: distinct effects in primary versus transformed cells. , 2010, Blood.

[20]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[21]  K. Chandy,et al.  The functional network of ion channels in T lymphocytes , 2009, Immunological reviews.

[22]  L. Chieco‐Bianchi,et al.  Modulation of mitochondrial K(+) permeability and reactive oxygen species production by the p13 protein of human T-cell leukemia virus type 1. , 2009, Biochimica et biophysica acta.

[23]  Vasilis Vasiliou,et al.  Human ATP-binding cassette (ABC) transporter family , 2009, Human Genomics.

[24]  J. Barata,et al.  PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. , 2008, The Journal of clinical investigation.

[25]  P. Pinton,et al.  Calcium and apoptosis: ER-mitochondria Ca2+ transfer in the control of apoptosis , 2008, Oncogene.

[26]  W. Telford,et al.  Side Population Analysis Using a Violet‐Excited Cell‐Permeable DNA Binding Dye , 2007, Stem cells.

[27]  K. Faber,et al.  Expression of Multidrug Resistance–Associated Proteins Predicts Prognosis in Childhood and Adult Acute Lymphoblastic Leukemia , 2005, Clinical Cancer Research.

[28]  A. di Pietro,et al.  Verapamil and Its Derivative Trigger Apoptosis through Glutathione Extrusion by Multidrug Resistance Protein MRP1 , 2004, Cancer Research.

[29]  Michael Pennington,et al.  K+ channels as targets for specific immunomodulation. , 2004, Trends in pharmacological sciences.

[30]  Andrew Crowe,et al.  In Vitro and In Situ Absorption of SDZ-RAD Using a Human Intestinal Cell Line (Caco-2) and a Single Pass Perfusion Model in Rats: Comparison with Rapamycin , 1998, Pharmaceutical Research.

[31]  D. Steinbach,et al.  The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype. , 2003, Blood.

[32]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[33]  M. Davey,et al.  Verapamil-stimulated glutathione transport by the multidrug resistance-associated protein (MRP1) in leukaemia cells. , 2001, Biochemical pharmacology.

[34]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[35]  J. Pancrazio,et al.  Verapamil-induced blockade of voltage-activated K+ current in small-cell lung cancer cells. , 1991, The Journal of pharmacology and experimental therapeutics.

[36]  T. Tsuruo,et al.  Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. , 1981, Cancer research.